03rd week of 2021 patent applcation highlights part 8 |
Patent application number | Title | Published |
20210015720 | SKIN AND HAND CLEANSING COMPOSITIONS COMPRISING SCRUBBING MATERIALS | 2021-01-21 |
20210015721 | NOVEL OCCLUSIVE COMPOSITIONS | 2021-01-21 |
20210015722 | PROCESS FOR THE PREPARATION OF MICROCAPSULES | 2021-01-21 |
20210015723 | LIQUID EYELINER AND MANUFACTURING METHOD THEREOF | 2021-01-21 |
20210015724 | GOLD AND PALMITOYL PENTAPEPTIDE-4 NANOPARTICLES | 2021-01-21 |
20210015725 | SKINCARE PRODUCT AND METHOD OF PREPARATION THEREOF | 2021-01-21 |
20210015726 | TITANIUM DIOXIDE | 2021-01-21 |
20210015727 | ALCOHOL BASED SANITIZER WITH IMPROVED DERMAL COMPATIBILITY AND FEEL | 2021-01-21 |
20210015728 | COMBAR FOR SKIN AND HAIR TREATMENT | 2021-01-21 |
20210015729 | FIRST AGENT FOR OXIDATION HAIR DYE OR HAIR DECOLORIZING AGENT | 2021-01-21 |
20210015730 | COMPOUND FOR USE IN PROTECTING SKIN | 2021-01-21 |
20210015731 | Foaming Topical Antimicrobial Cleaning Compositions | 2021-01-21 |
20210015732 | LIQUID LIPID COMPOSITE COMPOSITION FOR IMPROVING HAIR CONDITION | 2021-01-21 |
20210015733 | AEROGELS AND THEIR USE IN COSMETIC APPLICATIONS | 2021-01-21 |
20210015734 | Oral Care Products and Methods | 2021-01-21 |
20210015735 | Cosmetic Composition | 2021-01-21 |
20210015736 | HALOBACILLUS TRUEPERI TCI66207 AND BACTERIAL LYSATE THEREOF AND USE OF BACTERIAL LYSATE | 2021-01-21 |
20210015737 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | 2021-01-21 |
20210015738 | ORAL DISSOLVABLE FILM CONTAINING PSYCHEDELIC COMPOUND | 2021-01-21 |
20210015739 | Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | 2021-01-21 |
20210015740 | TOPICAL CANNABINOID COMPOSITIONS, DELIVERY SYSTEMS, AND USES FOR PAIN RELIEF | 2021-01-21 |
20210015741 | NEEDLE ASSISTED JET INJECTION ADMINISTRATION OF TESTOSTERONE COMPOSITIONS | 2021-01-21 |
20210015742 | Subcutaneous Biodegradable Naltrexone Implant And Accompanying Behavioral Program For Weight Loss In A Patient | 2021-01-21 |
20210015743 | TREATMENT OF IRRITABLE BOWEL AND INFLAMMATORY BOWEL DISEASE | 2021-01-21 |
20210015744 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | 2021-01-21 |
20210015745 | MODIFIED RELEASE DRUG POWDER COMPOSITION COMPRISING GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE | 2021-01-21 |
20210015746 | NICOTINE GEL | 2021-01-21 |
20210015747 | COMPOSITION FOR TREATING ONYCHOMYCOSIS | 2021-01-21 |
20210015748 | TOPICAL FORMULATIONS HAVING ENHANCED BIOAVAILABILITY | 2021-01-21 |
20210015749 | NANOCOCHLEATE FORMULATION AND METHOD OF PREPARING THE NANOCOCHLEATE FORMULATION | 2021-01-21 |
20210015750 | METHODS FOR CONTINUOUS MANUFACTURE OF LIPOSOMAL DRUG PRODUCTS | 2021-01-21 |
20210015751 | METHOD FOR PREPARING LIPOSOME COMPRISING ULTRASOUND REACTIVE MICROBUBBLE FOR DRUG DELIVERY AND LIPOSOME USING SAME | 2021-01-21 |
20210015752 | METHODS FOR PRODUCING PARTICLES OF AN ACTIVE INGREDIENT | 2021-01-21 |
20210015753 | FREEZE-DRIED MULTIPARTICULATE SOLID DOSAGE FORM | 2021-01-21 |
20210015754 | GASTRO-RETENTIVE SUSTAINED-RELEASE ORAL DOSAGE FORM OF A BILE ACID SEQUESTRANT | 2021-01-21 |
20210015755 | SECNIDAZOLE SOFT GELATIN CAPSULE AND METHODS AND USES THEREOF | 2021-01-21 |
20210015756 | NANOPARTICLES FOR USE FOR TREATING A NEURONAL DISORDER | 2021-01-21 |
20210015757 | DRUG DELIVERY BY PORE-MODIFIED MESOPOROUS SILICA NANOPARTICLES | 2021-01-21 |
20210015758 | Modular Particulars for Immunotherapy | 2021-01-21 |
20210015759 | CANNABINOID COMPOSITIONS AND PROCESSES FOR MAKING SAME | 2021-01-21 |
20210015760 | PHARMACEUTICAL FORMULATIONS CONTAINING GABOXADOL FOR THERAPEUTIC TREATMENT | 2021-01-21 |
20210015761 | SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG | 2021-01-21 |
20210015762 | COMPOSITIONS FOR TREATING OBESITY | 2021-01-21 |
20210015763 | CANNABIDIOL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION | 2021-01-21 |
20210015764 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | 2021-01-21 |
20210015765 | POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)B- UTANAMIDE | 2021-01-21 |
20210015766 | TOPICAL PREPARATION CONTAINING VITAMIN K1 AND PREPARATION METHOD THEREOF | 2021-01-21 |
20210015767 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | 2021-01-21 |
20210015768 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 2021-01-21 |
20210015769 | USE OF METFORMIN AND SODIUM BUTYRATE FOR TREATING CONDITIONS INDUCED BY CHRONIC INFLAMMATION | 2021-01-21 |
20210015770 | THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR CONTROLLED DRUG DELIVERY TO THE EAR | 2021-01-21 |
20210015771 | COMPOSITIONS AND METHODS FOR INDUCING DEFECATION | 2021-01-21 |
20210015772 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FIBROSIS | 2021-01-21 |
20210015773 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | 2021-01-21 |
20210015774 | TABLET OR COMPOSITION HAVING N-ACYL ETHANOLAMINE AND CANNABINOID | 2021-01-21 |
20210015775 | Methods and compositions for the treatment of sickle cell diseases and thalassemia | 2021-01-21 |
20210015776 | METHODS OF STABILIZATION OF LEVOTHYROXINE SODIUM TABLETS | 2021-01-21 |
20210015777 | HEALING TOPICAL COMPOSITION | 2021-01-21 |
20210015778 | Methods and Compositions for the Treatment of Sickle Cell Diseases and Thalassemia | 2021-01-21 |
20210015780 | MEDICAMENT HAVING ANTI-INFLAMMATORY BOWEL DISEASE FUNCTION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 2021-01-21 |
20210015781 | METHOD OF TREATING OR PREVENTING MOOD DISORDERS, MENTAL DISORDERS, AND/OR CHRONIC FATIGUE SYNDROME | 2021-01-21 |
20210015782 | CONTINUOUS ADMINISTRATION OF PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 2021-01-21 |
20210015783 | Pharmaceutical Compositions Containing Taxane-Cyclodextrin Complexes, Method of Making and Methods of Use | 2021-01-21 |
20210015784 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | 2021-01-21 |
20210015785 | COMBINATION OF A UBIQUITIN-CONJUGATING ENZYME COMPLEX INHIBITOR AND ANTIHYPERTENSIVE AND/OR HYPOGLYCEMIC DRUGS IN DIABETIC KIDNEY DISEASE | 2021-01-21 |
20210015786 | NANOEMULSION HYDROPHOBIC SUBSTANCES | 2021-01-21 |
20210015787 | COMPOSITIONS, METHODS, SYSTEMS AND/OR KITS FOR PREVENTING AND/OR TREATING NEOPLASMS | 2021-01-21 |
20210015788 | COMPOSITIONS | 2021-01-21 |
20210015789 | CANNABIDIOL PREPARATIONS AND ITS USES | 2021-01-21 |
20210015790 | ANTI-METHANOGENIC LOVASTATIN ANALOGS OR DERIVATIVES AND USES THEREOF | 2021-01-21 |
20210015791 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME WITH A CANNABINOID RECEPTOR ANTAGONIST | 2021-01-21 |
20210015792 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | 2021-01-21 |
20210015793 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | 2021-01-21 |
20210015794 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | 2021-01-21 |
20210015795 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS | 2021-01-21 |
20210015796 | TREATMENT USING DANTROLENE | 2021-01-21 |
20210015797 | Treatment For Inflammatory Disease | 2021-01-21 |
20210015798 | Ifetroban Treatment for Systemic Sclerosis | 2021-01-21 |
20210015799 | TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS | 2021-01-21 |
20210015800 | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | 2021-01-21 |
20210015801 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHY- RIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | 2021-01-21 |
20210015802 | METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF | 2021-01-21 |
20210015803 | SELECTIVE ANTI-CANCER AGENT EFFECTIVE FOR PREVENTION AND TREATMENT | 2021-01-21 |
20210015804 | FORMULATIONS OF (S)-3-AMINO-6-METHOXY-N-(3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPYL)-5-(TRI- FLUOROMETHYL)PICOLINAMIDE | 2021-01-21 |
20210015805 | TREATMENT FOR PARKINSON'S DISEASE | 2021-01-21 |
20210015806 | USE OF 5-FLUORO-4-(4-FLUORO-2-METHOXYPHENYL)-N-{4-[(S-METHYLSULFONIMIDOYL)- METHYL]PYRIDIN-2-YL}PYRIDIN-2-AMINE FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | 2021-01-21 |
20210015807 | ALK5 INHIBITORS AS SKELETAL MUSCLE HYPERTROPHY INDUCERS | 2021-01-21 |
20210015808 | READY-TO-ADMINISTER FENTANYL FORMULATIONS | 2021-01-21 |
20210015809 | ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | 2021-01-21 |
20210015810 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | 2021-01-21 |
20210015811 | METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES | 2021-01-21 |
20210015812 | Methods for Treating Antipsychotic-Induced Weight Gain | 2021-01-21 |
20210015813 | TREATMENT OF DEMYELINATING DISEASES | 2021-01-21 |
20210015814 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 2021-01-21 |
20210015815 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 2021-01-21 |
20210015816 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | 2021-01-21 |
20210015817 | SOLID-STATE FORMS OF ABEMACICLIB, THEIR USE AND PREPARATION | 2021-01-21 |
20210015818 | METHODS OF TREATING LIVER DISEASE | 2021-01-21 |
20210015819 | METHODS FOR TREATMENT OF CANCERS WITH EGFR ACTIVATING MUTATIONS | 2021-01-21 |
20210015820 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BETA-CATENIN-ASSOCIATED DISEASE OR DISORDER | 2021-01-21 |